- Home
- SSP vs GOSS Comparison
SSP vs GOSS Comparison
Compare SSP & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- GOSS
- Stock Information
- Founded
- SSP 1878
- GOSS 2015
- Country
- SSP United States
- GOSS United States
- Employees
- SSP N/A
- GOSS N/A
- Industry
- SSP Broadcasting
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- GOSS Health Care
- Exchange
- SSP Nasdaq
- GOSS Nasdaq
- Market Cap
- SSP 252.6M
- GOSS 262.5M
- IPO Year
- SSP 1988
- GOSS 2019
- Fundamental
- Price
- SSP $3.17
- GOSS $1.25
- Analyst Decision
- SSP Strong Buy
- GOSS Strong Buy
- Analyst Count
- SSP 1
- GOSS 3
- Target Price
- SSP $8.00
- GOSS $7.33
- AVG Volume (30 Days)
- SSP 906.8K
- GOSS 2.6M
- Earning Date
- SSP 08-07-2025
- GOSS 08-11-2025
- Dividend Yield
- SSP N/A
- GOSS N/A
- EPS Growth
- SSP N/A
- GOSS N/A
- EPS
- SSP 0.93
- GOSS N/A
- Revenue
- SSP $2,472,701,000.00
- GOSS $124,590,000.00
- Revenue This Year
- SSP N/A
- GOSS N/A
- Revenue Next Year
- SSP $9.51
- GOSS $91.14
- P/E Ratio
- SSP $3.57
- GOSS N/A
- Revenue Growth
- SSP 6.28
- GOSS N/A
- 52 Week Low
- SSP $1.36
- GOSS $0.66
- 52 Week High
- SSP $4.06
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- SSP 67.71
- GOSS 49.48
- Support Level
- SSP $2.70
- GOSS $1.20
- Resistance Level
- SSP $3.17
- GOSS $1.33
- Average True Range (ATR)
- SSP 0.22
- GOSS 0.10
- MACD
- SSP 0.03
- GOSS -0.02
- Stochastic Oscillator
- SSP 94.74
- GOSS 18.37
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.